Recent News

• 03.11.2025 - 2025.03.11 - 2025.03.12 : Leerink Partners Global Healthcare Conference
• 03.11.2025 - 2025.03.11 - 2025.03.12 : Leerink Partners Global Healthcare Conference
• 03.07.2025 - I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
• 02.18.2025 - I-Mab to Participate in Leerink Partners Global Healthcare Conference
• 02.11.2025 - February 11, 2025 4:00 PM EST - February 12, 2025 4:30 PM EST : Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
• 02.04.2025 - I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
• 01.08.2025 - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
• 01.06.2025 - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
• 01.06.2025 - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Recent Filings

• 03.07.2025 - EX-99.1 EX-99.1
• 03.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.27.2025 - EX-99.1 EX-99.1
• 02.05.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 01.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.13.2025 - EX-99.1 EX-99.1
• 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.08.2025 - EX-99.1 EX-99.1